Physician profile
John S Thomas
NPI 1558393470
$2,121.25
in general payments reported to CMS, 2019-2025
33 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $85.12 · 2021: $379 · 2022: $343 · 2023: $194 · 2024: $271 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $394.39 | 2019-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Conformable Thoracic Endoprosthesis |
| Endologix LLC | $368.40 | 2024-2025 | Alto Abdominal Stent Graft System, Endocross Device, Torus Stent Graft System |
| Intuitive Surgical, INC. | $279.82 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $179.70 | 2019-2021 | |
| Ethicon US, LLC | $126.88 | 2020-2025 | Echelon; Endopath, Evarrest, Vistaseal |
| Elucent Medical | $114.20 | 2021-2025 | |
| Conmed Corporation | $64.56 | 2019-2023 | Visiclear, Airseal |
| Tela Bio, INC. | $60.41 | 2021-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $56.22 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $41.05 | 2024 | Xarelto |
| Portola Pharmaceuticals, LLC | $38.81 | 2019 | |
| Ossur Americas, INC. | $34.63 | 2024-2025 | |
| Boston Scientific Corporation | $27.40 | 2023-2025 | Varithena Administration Pack, Spyglass |
| Kci USA, INC. | $26.24 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.26 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $23.04 | 2025 | Artegraft Vascular Graft |
| Allergan, INC. | $22.62 | 2022 | |
| Solventum Corporation | $22.31 | 2024 | Activ.A.C. |
| Cardinal Health 414 LLC | $18.42 | 2019 | |
| Hologic Sales and Service, LLC | $16.89 | 2023 | Trunode |
| Terumo Medical Corporation | $16.67 | 2021 | |
| Acera Surgical, INC. | $15.96 | 2024 | Restrata Wound Matrix |
| Cook Medical LLC | $15.92 | 2024 | Zenith Spiral-Z |
| Medtronic, INC. | $15.72 | 2023 | Signia |
| Depuy Synthes Sales INC. | $13.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.66 | 2021 | |
| Avita Medical Americas, LLC | $13.57 | 2025 | Recell, Permeaderm, Cohealyx |
| Smith+Nephew, INC. | $13.56 | 2019 | |
| Becton, Dickinson and Company | $13.24 | 2023 | Powerport Clearvue Isp Implantable Port |
| Focal Therapeutics, INC. | $12.86 | 2021 | |
| Urgo Medical North America, LLC | $12.75 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Abbott Laboratories | $12.56 | 2019 | |
| Shockwave Medical, INC | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.